Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

📆 28/07/2023 22:48:00
📰 Forbes

⏱ Reading Time:
15 sec. here
2 min. at publisher
📊 Quality Score:
News: 9%
Publisher: 53%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

Escrever Comentário

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion AcquisitionBiogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
Fonte: Forbes - 🏆 394. / 53 Consulte Mais informação »

Biogen to bulk up rare disease treatments with $7 billion Reata acquisitionBiogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
Fonte: WashTimes - 🏆 235. / 63 Consulte Mais informação »